Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
Hongchao Pan, Richárd Pető, Ana María Henao-Restrepo, et al.
The Lancet (2022) Vol. 399, Iss. 10339, pp. 1941-1953
Open Access | Times Cited: 332

Showing 1-25 of 332 citing articles:

Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 382
Therapeutic advances in COVID-19
Naoka Murakami, Robert Hayden, Thomas Hills, et al.
Nature Reviews Nephrology (2022) Vol. 19, Iss. 1, pp. 38-52
Open Access | Times Cited: 128
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Cong Sun, Chu Xie, Guo‐Long Bu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 113
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials
Alain Amstutz, Benjamin Speich, France Mentré, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 5, pp. 453-464
Open Access | Times Cited: 86
Remdesivir for the treatment of COVID-19
Felicitas Grundeis, Kelly Ansems, Karolina Dahms, et al.
Cochrane library (2023) Vol. 2023, Iss. 1
Closed Access | Times Cited: 77
Innate immunity, cytokine storm, and inflammatory cell death in COVID-19
Rajendra Karki, Thirumala‐Devi Kanneganti
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 72
Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis
Todd C. Lee, Srinivas Murthy, Olivier Del Corpo, et al.
Clinical Microbiology and Infection (2022) Vol. 28, Iss. 9, pp. 1203-1210
Open Access | Times Cited: 71
Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice
Ju Hwan Jeong, Santosh Chokkakula, Seong Cheol Min, et al.
Antiviral Research (2022) Vol. 208, pp. 105430-105430
Open Access | Times Cited: 67
Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance
Jonathan Daniel Ip, Allen Wing‐Ho Chu, Wan-Mui Chan, et al.
EBioMedicine (2023) Vol. 91, pp. 104559-104559
Open Access | Times Cited: 67
Innate immune inflammatory cell death: PANoptosis and PANoptosomes in host defense and disease
Wen Chen, Jessica M. Gullett, Rebecca E. Tweedell, et al.
European Journal of Immunology (2023) Vol. 53, Iss. 11
Open Access | Times Cited: 64
Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China
Liyan Yang, Zhonglei Wang
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115503-115503
Open Access | Times Cited: 63
Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model
Bin Tan, Xiaoming Zhang, Ahmadullah Ansari, et al.
Science (2024) Vol. 383, Iss. 6690, pp. 1434-1440
Open Access | Times Cited: 41
The Integration of Clinical Trials With the Practice of Medicine
Derek C. Angus, Alison J. Huang, Roger Lewis, et al.
JAMA (2024) Vol. 332, Iss. 2, pp. 153-153
Closed Access | Times Cited: 22
COVID-19 drug discovery and treatment options
Jasper Fuk‐Woo Chan, Shuofeng Yuan, Hin Chu, et al.
Nature Reviews Microbiology (2024) Vol. 22, Iss. 7, pp. 391-407
Closed Access | Times Cited: 17
Enhancing sepsis biomarker development: key considerations from public and private perspectives
Jean‐François Llitjos, Enitan D. Carrol, Marcin F. Osuchowski, et al.
Critical Care (2024) Vol. 28, Iss. 1
Open Access | Times Cited: 15
Real-world evidence of remdesivir in formerly hospitalized COVID-19 patients: patient-reported and functional outcomes
Dorottya Fésü, Enikő Bárczi, Balázs Csoma, et al.
BMC Infectious Diseases (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United States
Anand P. Chokkalingam, Jennifer Hayden, Jason D. Goldman, et al.
JAMA Network Open (2022) Vol. 5, Iss. 12, pp. e2244505-e2244505
Open Access | Times Cited: 51
Oral GS-441524 derivatives: Next-generation inhibitors of SARS‐CoV‐2 RNA‐dependent RNA polymerase
Zhonglei Wang, Liyan Yang, Xian-qing Song
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 47
The evolving landscape of pulmonary arterial hypertension clinical trials
Jason Weatherald, Athénaïs Boucly, Anthony E. Peters, et al.
The Lancet (2022) Vol. 400, Iss. 10366, pp. 1884-1898
Open Access | Times Cited: 44
Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial
Olli Nevalainen, Saana Horstia, Sanna Laakkonen, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 40
Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice
Essy Mozaffari, Aastha Chandak, Robert Gottlieb, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 12, pp. 1626-1634
Open Access | Times Cited: 33
Drug treatment of COVID-19 infection
Grace Lui, Giovanni Guaraldi
Current Opinion in Pulmonary Medicine (2023) Vol. 29, Iss. 3, pp. 174-183
Open Access | Times Cited: 30
An observational study on factors associated with ICU mortality in Covid-19 patients and critical review of the literature
Athina Lavrentieva, Evangelos Kaimakamis, Vassileios Voutsas, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 30
Remdesivir: A Review in COVID-19
Hannah A. Blair
Drugs (2023) Vol. 83, Iss. 13, pp. 1215-1237
Open Access | Times Cited: 28
Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis
Mykhailo Buchynskyi, Iryna Kamyshna, Katerina Lyubomirskaya, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top